N Engl J Med. 2010 Sep 16;363(12):1180-2. doi: 10.1056/NEJMe1005856.

From palliation to targeted therapy in myelofibrosis.

Vannucchi AM.

Comment on

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. [N Engl J Med. 2010]
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, et al. N Engl J Med. 2010 Sep 16; 363(12):1117-27.

PMID:: 20843255; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

JAK inhibition in myelofibrosis. [N Engl J Med. 2010]
JAK inhibition in myelofibrosis.
Arellano-Rodrigo E, Alvarez-Larrán A. N Engl J Med. 2010 Dec 16; 363(25):2464; author reply 2464-5; discussion 2465.
Ruxolitinib for myelofibrosis. [N Engl J Med. 2012]
Ruxolitinib for myelofibrosis.
Haznedaroglu IC. N Engl J Med. 2012 May 24; 366(21):2032; author reply 2032-5.
Ruxolitinib for myelofibrosis. [N Engl J Med. 2012]
Ruxolitinib for myelofibrosis.
Koschmieder S, Koppelle A, Seifert H. N Engl J Med. 2012 May 24; 366(21):2031-2; author reply 2032-4.
Review Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. [Postgrad Med. 2013]
Review Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S. Postgrad Med. 2013 Jan; 125(1):128-35.
Review Ruxolitinib for the treatment of myelofibrosis. [Drugs Today (Barc). 2011]
Review Ruxolitinib for the treatment of myelofibrosis.
Ostojic A, Vrhovac R, Verstovsek S. Drugs Today (Barc). 2011 Nov; 47(11):817-27.

See reviews... See all...

Cited by 3 PubMed Central articles

Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. [Ther Adv Hematol. 2012]
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
Harrison C, Vannucchi AM. Ther Adv Hematol. 2012 Dec; 3(6):341-54.
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. [Ther Adv Hematol. 2011]
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.
Vannucchi AM, Pieri L, Guglielmelli P. Ther Adv Hematol. 2011 Feb; 2(1):21-32.
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. [Blood. 2011]
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, et al. Blood. 2011 Aug 25; 118(8):2069-76. Epub 2011 Jul 1.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

From palliation to targeted therapy in myelofibrosis.
From palliation to targeted therapy in myelofibrosis.
N Engl J Med. 2010 Sep 16 ;363(12):1180-2. doi: 10.1056/NEJMe1005856.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

From palliation to targeted therapy in myelofibrosis.

Comment on

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information